AstraZeneca and Daiichi Sankyo’s Enhertu receives EU approval
Specifically engineered antibody treats HER2-positive metastatic breast cancer
Read More
Tag: Daiichi Sankyo
Daiichi Sankyo and AstraZeneca’s Enhertu delivers promising trial results
Enhertu reduced the risk of disease progression or death compared to chemotherapy in certain patients with metastatic breast cancer
Read More
ViGeneron and Daiichi Sankyo to develop therapy for eye diseases
Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates
Read More
Enhertu reduces breast cancer disease progression or death by 72%
‘Groundbreaking results’ for the treatment of HER2-positive metastatic breast cancer
Read More
Enhertu improves progression-free survival in breast cancer trial
Trial compared Enhertu with T-DM1 in patients with HER2-positive breast cancer
Read More
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer
Decision is based on results from the Phase II DESTINY-Breast01 trial
Read More
Daiichi Sankyo inks digital partnership for atrial fibrillation
Collaborative agreement will focus on improving detection and diagnosis of AF
Read More
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments
In the UK, over seven million people are affected by cardiovascular disease
Read More
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK
Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Read More
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials
Datopotamab deruxtecan and Enhertu were evaluated in non-small cell lung cancer patients
Read More
AZ, Daiichi Sankyo’s Enhertu wins US approval for HER2-positive gastric cancer
Approval is based on results from the Phase III DESTINY-Gastric01 trial
Read More
Two medicines accepted for use by NHS Scotland
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
